(CercleFinance.com) – Pfizer estimated on Thursday that it had a ‘robust’ portfolio of drugs in oncology since the finalization of the acquisition of Seagen at the end of 2023.
On the occasion of a day dedicated to innovation held yesterday in New York, the American biopharmaceutical group explained that it intended to focus its research and development (R&D) work on three classes of anticancer drugs.
These are, according to the laboratory, small molecules, antibody-drug conjugates and bispecific antibodies.
In terms of pathologies, Pfizer explains that it wants to focus on breast cancer, prostate and bladder cancers, but also on certain myelomas and lymphomas such as Hodgkin’s disease, as well as lung and breast cancers. head and neck.
With this ‘pipeline’, the group believes it will be able to have at least eight potential ‘blockbusters’ by 2030, that is to say drugs representing an annual turnover of more than billion dollars.
With this in mind, the first half of 2025 already promises to be decisive, specifies the company, with the expected publication of the results of seven phase 3 clinical studies.
Following these announcements, Pfizer shares rose by around 1% on Friday on the New York Stock Exchange.
Copyright (c) 2024 CercleFinance.com. All rights reserved.
Are you following this action?
Receive all the information on Pfizer in real time: